Shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) hit a new 52-week low on Monday . The company traded as low as $2.20 and last traded at $2.23, with a volume of 892602 shares trading hands. The stock had previously closed at $2.33.
Analyst Ratings Changes
A number of research analysts have weighed in on ABCL shares. Benchmark restated a "hold" rating on shares of AbCellera Biologics in a report on Monday, March 3rd. KeyCorp decreased their price objective on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Finally, Stifel Nicolaus reduced their price target on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, February 28th.
Get Our Latest Stock Report on ABCL
AbCellera Biologics Trading Up 5.0 %
The firm has a fifty day moving average price of $2.97 and a 200 day moving average price of $2.82. The firm has a market cap of $750.93 million, a PE ratio of -4.13 and a beta of 0.45.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ABCL. GSA Capital Partners LLP raised its holdings in shares of AbCellera Biologics by 991.3% during the 3rd quarter. GSA Capital Partners LLP now owns 241,866 shares of the company's stock worth $629,000 after acquiring an additional 219,703 shares during the period. Pier 88 Investment Partners LLC increased its position in shares of AbCellera Biologics by 21.0% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 195,500 shares of the company's stock worth $508,000 after purchasing an additional 33,880 shares during the last quarter. Clarkston Capital Partners LLC acquired a new stake in shares of AbCellera Biologics during the 3rd quarter worth about $57,000. Walleye Capital LLC acquired a new stake in shares of AbCellera Biologics during the 3rd quarter worth about $668,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of AbCellera Biologics during the 3rd quarter worth about $162,000. Hedge funds and other institutional investors own 61.42% of the company's stock.
AbCellera Biologics Company Profile
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Further Reading
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
